These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35693078)

  • 41. Neoadjuvant FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer: An intention to treat analysis.
    Barenboim A; Lahat G; Geva R; Nachmany I; Nakache R; Goykhman Y; Brazowski E; Rosen G; Isakov O; Wolf I; Klausner JM; Lubezky N
    Eur J Surg Oncol; 2018 Oct; 44(10):1619-1623. PubMed ID: 30146251
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review.
    Napolitano F; Formisano L; Giardino A; Girelli R; Servetto A; Santaniello A; Foschini F; Marciano R; Mozzillo E; Carratù AC; Cascetta P; De Placido P; De Placido S; Bianco R
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31337045
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.
    Faris JE; Blaszkowsky LS; McDermott S; Guimaraes AR; Szymonifka J; Huynh MA; Ferrone CR; Wargo JA; Allen JN; Dias LE; Kwak EL; Lillemoe KD; Thayer SP; Murphy JE; Zhu AX; Sahani DV; Wo JY; Clark JW; Fernandez-del Castillo C; Ryan DP; Hong TS
    Oncologist; 2013; 18(5):543-8. PubMed ID: 23657686
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Nontrial, real-world outcomes in unresectable locally advanced pancreatic cancer: Chemotherapy and chemoradiation is the standard while surgery is uncommon.
    Ramaswamy A; Jandyal S; Ostwal V; Engineer R; Lewis S; Bose S; Pande N; Shrikhande SV
    Indian J Cancer; 2017; 54(3):530-534. PubMed ID: 29798952
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, multicenter phase II trial (NEOLAP-AIO-PAK-0113).
    Hartlapp I; Valta-Seufzer D; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens UM; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Anger F; Germer CT; Stang A; Kimmel B; Heinemann V; Kunzmann V;
    ESMO Open; 2022 Aug; 7(4):100552. PubMed ID: 35970013
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Contemporary Management of Borderline Resectable and Locally Advanced Unresectable Pancreatic Cancer.
    Shaib WL; Ip A; Cardona K; Alese OB; Maithel SK; Kooby D; Landry J; El-Rayes BF
    Oncologist; 2016 Feb; 21(2):178-87. PubMed ID: 26834159
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Meta-analysis of FOLFIRINOX-based neoadjuvant therapy for locally advanced pancreatic cancer.
    Chen Z; Lv Y; Li H; Diao R; Zhou J; Yu T
    Medicine (Baltimore); 2021 Jan; 100(3):e24068. PubMed ID: 33546009
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Induction Chemotherapy with FOLFIRINOX for Locally Advanced Pancreatic Cancer: A Simple Scoring System to Predict Effect and Prognosis.
    Tanaka M; Heckler M; Mihaljevic AL; Ei S; Klaiber U; Heger U; Büchler MW; Hackert T
    Ann Surg Oncol; 2023 Apr; 30(4):2401-2408. PubMed ID: 36153440
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A phase II study of stereotactic radiotherapy after FOLFIRINOX for locally advanced pancreatic cancer (LAPC-1 trial): Long-term outcome.
    Teriaca MA; Loi M; Suker M; Eskens FALM; van Eijck CHJ; Nuyttens JJ
    Radiother Oncol; 2021 Feb; 155():232-236. PubMed ID: 33217500
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical impact of multimodal treatment including chemoradiotherapy, conversion surgery and postoperative chemotherapy for borderline resectable and unresectable locally advanced pancreatic cancer without disease progression after gemcitabine plus nab-paclitaxel.
    Umezawa R; Mizuma M; Nakagawa K; Yamamoto T; Takahashi N; Suzuki Y; Kishida K; Omata S; Unno M; Jingu K
    Pancreatology; 2023 Sep; 23(6):650-656. PubMed ID: 37453848
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Conversion surgery for initially unresectable pancreatic cancer: current status and unresolved issues.
    Yoshitomi H; Takano S; Furukawa K; Takayashiki T; Kuboki S; Ohtsuka M
    Surg Today; 2019 Nov; 49(11):894-906. PubMed ID: 30949842
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FOLFIRINOX for locally advanced and metastatic pancreatic cancer: single institution retrospective review of efficacy and toxicity.
    Gunturu KS; Yao X; Cong X; Thumar JR; Hochster HS; Stein SM; Lacy J
    Med Oncol; 2013 Mar; 30(1):361. PubMed ID: 23271209
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Optimizing Indications for Conversion Surgery Based on Analysis of 454 Consecutive Japanese Cases with Unresectable Pancreatic Cancer Who Received Modified FOLFIRINOX or Gemcitabine Plus Nab-paclitaxel: A Single-Center Retrospective Study.
    Ushida Y; Inoue Y; Oba A; Mie T; Ito H; Ono Y; Sato T; Ozaka M; Sasaki T; Saiura A; Sasahira N; Takahashi Y
    Ann Surg Oncol; 2022 Aug; 29(8):5038-5050. PubMed ID: 35294658
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Neoadjuvant modified FOLFIRINOX and chemoradiation therapy for locally advanced pancreatic cancer improves resectability.
    Nanda RH; El-Rayes B; Maithel SK; Landry J
    J Surg Oncol; 2015 Jun; 111(8):1028-34. PubMed ID: 26073887
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma.
    Lee JL; Kim SC; Kim JH; Lee SS; Kim TW; Park DH; Seo DW; Lee SK; Kim MH; Kim JH; Park JH; Shin SH; Han DJ
    Surgery; 2012 Nov; 152(5):851-62. PubMed ID: 22682078
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nab-paclitaxel plus gemcitabine in patients with locally advanced pancreatic cancer (LAPACT): a multicentre, open-label phase 2 study.
    Philip PA; Lacy J; Portales F; Sobrero A; Pazo-Cid R; Manzano Mozo JL; Kim EJ; Dowden S; Zakari A; Borg C; Terrebonne E; Rivera F; Sastre J; Bathini V; López-Trabada D; Asselah J; Saif MW; Shiansong Li J; Ong TJ; Nydam T; Hammel P
    Lancet Gastroenterol Hepatol; 2020 Mar; 5(3):285-294. PubMed ID: 31953079
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase II study of induction chemotherapy with gemcitabine plus 5-fluorouracil followed by gemcitabine-based concurrent chemoradiotherapy for unresectable locally advanced pancreatic cancer.
    Kurt E; Kurt M; Kanat O; Cetintas SK; Aygun S; Palazoglu T; Ozkan L; Evrensel T; Kaya E; Manavoglu O
    Tumori; 2006; 92(6):481-6. PubMed ID: 17260487
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Conversion therapy, palliative chemotherapy and surgery, which of these is the best treatment for locally advanced and advanced pancreatic cancer?
    Wang M; Zhu P; Chen Z; Yang L
    Anticancer Drugs; 2022 Jan; 33(1):e686-e691. PubMed ID: 34459461
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Intensified Neoadjuvant Chemotherapy with Nab-Paclitaxel plus Gemcitabine Followed by FOLFIRINOX in a Patient with Locally Advanced Unresectable Pancreatic Cancer.
    Kunzmann V; Herrmann K; Bluemel C; Kapp M; Hartlapp I; Steger U
    Case Rep Oncol; 2014 Sep; 7(3):648-55. PubMed ID: 25408659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.